Table 1.
Demographic and baseline characteristics of 209 metastatic nasopharyngeal carcinoma patients.
| Characteristic | Number (%) | AAPR<0.447, Number (%) | AAPR≥0.447, Number (%) | P value |
|---|---|---|---|---|
| Gender (male/female) | 179/30 (85.6/14.4) | 60/7 (89.6/10.4) | 119/23(83.8/16.2) | 0.299 |
| Age, years (median/range) | 45 (14-72) | 43 (14-69) | 46 (26-72) | 0.266 |
| KPS (≥90/<90) | 170/39 (81.3/18.7) | 50/17 (74.6/25.4) | 120/22 (84.5/15.5) | 0.091 |
| Number of involved sites (one/multiple) | 104/105 (49.8/50.2) | 31/36 (46.3/53.7) | 73/69 (51.4/48.6) | 0.554 |
| Synchronous metastasis (yes/no) | 52/157 (24.9/75.1) | 19/48 (28.4/71.6) | 33/109 (23.2/76.8) | 0.493 |
| Liver metastasis (yes/no) | 73/136 (34.9/65.1) | 33/34 (49.3/50/7) | 40/102 (28.2/71.8) | 0.005 |
| Lung metastasis (yes/no) | 95/114 (45.5/54.5) | 28/39 (41.8/58.2) | 67/75 (47.2/52.8) | 0.552 |
| Bone metastasis (yes/no) | 87/122 (41.6/58.4) | 39/28 (58.2/41.8) | 48/94 (33.8/66.2) | 0.001 |
| Serum LDH,U/L (median/range) | 202 (25-3765) | 273 (25-3765) | 185 (111-1909) | 0.004 |
| Albumin (median/range) | 42.5 (27.4-71.3) | 40 (27.4-49.0) | 43.8 (30.8-71.3) | <0.001 |
| ALP (median/range) | 77 (9.0-644.2) | 121 (77.0-644.2) | 65.6 (9.0-102.6) | <0.001 |
| EBV-DNA, copies/ml (median/range) | 4.67×104/0-9.19×107 | 5.59×105/0-9.19×107 | 3.49×104/0-8.87×106 | 0.001 |
| Chemotherapy regimen (TPF/PF/TP) | 108/77/24 (51.7/36.8/11.5) | 30/29/8 (44.8/44.3/11.9) | 78/48/16 (54.9/33.8/11.3) | 0.361 |
| Treatment response (CR+PR/PD+SD) | 147/62 (70.3/29.7) | 43/24 (64.2/35.8) | 104/38 (73.2/26.8) | 0.197 |